Press releases

Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology

Next-generation balloon catheter technology catheter developed specifically to address physicians' needs in optimizing coronary stent deployment

Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems

Presentations to include analyses from SYNTAX trial, as well as clinical data supporting the performance of drug-eluting stents

Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures

Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia

ACUITY Break-Away™ Lead Delivery System designed to place leads in veins of varying sizes, including difficult-to-access veins

Approval includes specific indication for treatment of diabetic patients

Upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data

Presentations will provide new insights for physicians who treat patients with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)

Results of study using Boston Scientific's WallFlex® Duodenal Stent presented at Digestive Disease Week®

EVIDENCE Trial to study Boston Scientific's Precision Plus™ Spinal Cord Stimulator System

Positive results to be presented for SpyGlass® Direct Visualization System, Radial Jaw® 4 Biopsy Forceps and WallFlex® Duodenal Stents

Educational forum includes lab training sessions and online community for urogynecologists, urologists and surgical gynecologists

Agreement relates to product advisories issued in 2005, before Boston Scientific acquired Guidant

Company records $1.8 billion goodwill impairment charge

Major advance in guidewire technology provides exceptional torque and flexibility for coronary procedures

A live webcast and replay of the January 11, 2011 conference will be available. Learn how to tune in.

A live webcast and replay of the May 4, 2011 conference will be available

Exclusive agreement promotes access to testing solutions for female urinary incontinence

Company is positioned to fully meet customer demand for COGNIS and TELIGEN within 24 hours

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2010...

Company's CRT-Ds recommended for asymptomatic and mild heart failure patients

Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System

Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberte® Stents in AMI patients

Analysis of the data presented at the American College of Cardiology Annual Scientific Sessions

Manufacturing process changes were not submitted for FDA approval; no indication that changes pose any risk to patient safety

First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries

Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent

A webcast of the March 2 session will be available. Learn how to tune in live or watch the replay

Article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator

New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness

"We delivered a quarter in line with expectations," said Ray Elliott, President and CEO

Settles three patent disputes with Johnson & Johnson (J&J) that date back to 2003

The patents relate to coatings (drug and polymer) for drug-eluting stents

Boston Scientific will webcast its February 11 conference call with financial results and business highlights for Q4 and FY 2009. Learn how to tune in.

Multi-center, prospective study plans to enroll 187 patients at 11 centers worldwide over the next 18 months

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A webcast of the January 12 session will be available. Learn how to tune in live or watch the replay

MAPS clinical trial studying the coiling of intracranial aneurysms reaches its goal of 630 patients, enrolled at 47 hospitals in 11 countries

Company to contribute data to industry-sponsored Dual Antiplatelet Therapy (DAPT) Study

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...

Former Tyco executive "will bring an impressive range of global management experience to our Board," said Pete Nicholas, Chairman of the Board

Company to use the net proceeds for general corporate purposes, including prepaying its bank term loan due April 2011

Company expects the offering to close on December 14, 2009, subject to standard closing conditions

A webcast of the December 1 session will be available. Learn how to tune in live or watch the replay

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Results from two clinical studies will be presented at the Global Congress for Minimally Invasive Gynecology (AAGL)

COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices

Company updates third quarter financial results and full-year 2009 guidance

Third-generation drug-eluting stent now available in CE Mark countries

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...

Company to webcast its conference call on October 20. Learn how to tune in

Three models of stenting system now available for palliative treatment of malignant common bile duct strictures

Study to determine which device programming strategy best minimizes the occurrence of unnecessary therapy in ICD and CRT-D patients

Agreement will settle more than a dozen lawsuits involving intellectual property in the interventional cardiology arena

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Results support benefits of paclitaxel-eluting stents in diabetic patients

Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent

Both drug-eluting stents performed well in diabetic patients

Intravascular Ultrasound (IVUS) technology designed to provide physicians a 360-degree view inside the heart and coronary vessels

PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent

Scientific symposium presentations to include clinical data on TAXUS and PROMUS stents

Agreement promotes access to testing solutions for female urinary incontinence

A live webcast and replay of the September 15 healthcare conference will be available.

A live webcast and replay of the September 9 session will be available.

Findings provide additional support for PCI as a viable treatment option for patients with complex coronary anatomy

The mortality reduction trend was also observed in high-risk patients with severely reduced heart function

Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC

Dr. Ken Stein to join CRM group

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European...

Statement from Pete Nicholas, Chairman of the Board, pays tribute to Sen. Kennedy's dedication to providing access to quality health care

Final results from the MADIT-CRT trial will be presented on Tuesday, September 1

A live webcast and replay of the August 5 session will be available.

Election of Bartlett and Byrnes increases the Boston Scientific Board to 13 members

"We delivered sales and earnings at the high end of our guidance range,” Ray Elliott, President and CEO

Longest available drug-eluting stent strengthens Company's broad portfolio

System remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status

Learn how to tune in or find the replay of the July 21 conference call

“We are confident Ray offers the right combination of experience, results and talents for Boston Scientific going forward,” said board chairman Pete Nicholas

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients NATICK, Mass., June 23 /PRNewswire-FirstCall/ -- Boston...

A live webcast and replay of the June 24th conference session will be available.

Presentations to feature results on pelvic floor reconstruction systems and mid-urethral sling systems

Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system NATICK, Mass., May 28 /PRNewswire-FirstCall/ --...

SpyGlass® Direct Visualization System can now be used for diagnostic and therapeutic procedures for pancreatic disease NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific...

"We are grateful for their service to Boston Scientific and its customers, patients and shareholders," said Pete Nicholas, Chairman of the Board

Specifically designed for treating small coronary vessels; joins the TAXUS® Express® Atom™ Stent as the only drug-eluting stents approved for small vessel use in the U.S.

Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping

ORION clinical trial to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of economic and quality of life outcomes,...

Boston Scientific Corporation (NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating outlook to positive from stable, while...

Results support previously announced outcomes with PCI and CABG in patients with left main coronary disease

TAXUS® Element™ Drug-Eluting Stent is now available in select markets worldwide

Online tools will help physicians determine treatment strategies

A live webcast and replay of the May 22 conference will be available.

Presentations to include additional analyses from the landmark SYNTAX trial

ALTITUDE analysis presented at the Heart Rhythm Society Scientific Sessions

Analysis indicates that one life is now saved for every six patients who receive an ICD

Donation marks the beginning of Company's agreement to provide the non-profit organization with CRM devices that would otherwise remain unused